A young adult patient has been taking an antidepressant medication for several weeks and reports having increased thoughts of suicide. The nurse questions further and learns that the patient has attempted suicide more than once in the past. The patient identifies a concrete plan for committing suicide. The nurse will contact the provider to discuss:

Ergotamine and other ergot-derived antimigraine medications cause vasoconstriction by stimulating serotonin and adrenergic receptors in vascular smooth muscle. Excessive dosing or prolonged use can lead to systemic vasospasm, reducing blood flow to the extremities. This can produce ischemic symptoms such as cold, pale limbs and paresthesia. Recognizing drug-induced vascular complications is essential in patients being treated for migraine disorders.

Rationale:
A. Ergotamine withdrawal is not a recognized clinical syndrome. Unlike dependence-producing substances, ergot derivatives do not cause a classic withdrawal pattern characterized by rebound systemic symptoms. The presentation of cold, pale extremities suggests vasoconstriction rather than withdrawal effects.

B. Severe migraine symptoms typically include unilateral pulsating headache, nausea, photophobia, and phonophobia. While migraines can cause neurologic symptoms such as aura, they do not cause peripheral ischemic signs like cool, pale extremities.

C. Ergotism is caused by excessive exposure to ergot-derived medications such as ergotamine. It results in intense peripheral vasoconstriction leading to ischemia, numbness, cold extremities, and pallor. Severe cases may progress to gangrene if not promptly recognized and treated by discontinuing the offending agent.

D. Sumatriptan side effects typically include transient sensations such as flushing, dizziness, or chest tightness due to vasoconstrictive activity, but it rarely causes severe peripheral ischemia. The symptoms described (cool, pale hands and feet with numbness) are more consistent with prolonged ergot-induced vasospasm rather than triptan adverse effects.

Postoperative patients receiving patient-controlled analgesia (PCA) with opioids such as Morphine sulfate are at risk for opioid-induced respiratory depression and central nervous system suppression. Over-sedation, bradypnea, hypotension, and altered mental status are warning signs of opioid toxicity. Pupillary changes, lethargy, and reduced respiratory rate indicate a potentially life-threatening overdose. Immediate intervention focuses on airway protection, reversal of opioid effects, and hemodynamic stabilization.

Rationale:
A. Noting the effectiveness of analgesia is inappropriate because the patient shows signs of opioid toxicity rather than therapeutic pain control. Drowsiness, respiratory depression, hypotension, and altered mental status indicate overdose rather than adequate analgesia. Documenting effectiveness at this stage would delay urgent intervention and compromise patient safety.

B. Discussing possible opioid dependence is not the priority in an acute clinical deterioration. The immediate concern is respiratory depression and cardiovascular instability, which require urgent reversal and supportive care. Dependence assessment is a long-term consideration and does not address the current life-threatening condition.

C. Encouraging the patient to turn, cough, and take deep breaths may be useful in mild sedation but is unsafe in this scenario. The patient has a respiratory rate of 10 breaths per minute and signs of significant CNS depression, indicating opioid overdose. Stimulation alone is insufficient and delays definitive treatment.

D. The findings are consistent with opioid-induced respiratory depression requiring emergency reversal with an opioid antagonist such as Naloxone. Naloxone rapidly displaces opioids from receptors, restoring respiratory drive. The nurse should also prepare for ventilatory support because rebound sedation may occur, and airway protection may be necessary to stabilize oxygenation and circulation.